Celldex Therapeutics Inc (CLDX)
37.02
-0.75
(-1.99%)
USD |
NASDAQ |
Apr 24, 16:00
37.01
-0.01
(-0.03%)
After-Hours: 20:00
Celldex Therapeutics Cash from Financing (TTM): 218.46M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 218.46M |
| September 30, 2023 | 2.479M |
| June 30, 2023 | 4.528M |
| March 31, 2023 | 4.466M |
| December 31, 2022 | 4.076M |
| September 30, 2022 | 3.107M |
| June 30, 2022 | 272.70M |
| March 31, 2022 | 272.60M |
| December 31, 2021 | 272.37M |
| September 30, 2021 | 271.99M |
| June 30, 2021 | 4.584M |
| March 31, 2021 | 169.66M |
| December 31, 2020 | 171.23M |
| September 30, 2020 | 173.60M |
| June 30, 2020 | 171.58M |
| March 31, 2020 | 13.73M |
| December 31, 2019 | 16.26M |
| September 30, 2019 | 17.40M |
| June 30, 2019 | 20.48M |
| March 31, 2019 | 21.54M |
| December 31, 2018 | 29.44M |
| September 30, 2018 | 44.33M |
| June 30, 2018 | 50.06M |
| March 31, 2018 | 50.46M |
| December 31, 2017 | 51.29M |
| Date | Value |
|---|---|
| September 30, 2017 | 36.12M |
| June 30, 2017 | 33.15M |
| March 31, 2017 | 27.10M |
| December 31, 2016 | 14.48M |
| September 30, 2016 | 11.52M |
| June 30, 2016 | 3.954M |
| March 31, 2016 | 1.672M |
| December 31, 2015 | 193.15M |
| September 30, 2015 | 192.84M |
| June 30, 2015 | 192.41M |
| March 31, 2015 | 192.23M |
| December 31, 2014 | 1.171M |
| September 30, 2014 | 184.71M |
| June 30, 2014 | 185.03M |
| March 31, 2014 | 175.79M |
| December 31, 2013 | 289.60M |
| September 30, 2013 | 125.62M |
| June 30, 2013 | 134.58M |
| March 31, 2013 | 142.35M |
| December 31, 2012 | 79.76M |
| September 30, 2012 | 60.31M |
| June 30, 2012 | 50.71M |
| March 31, 2012 | 87.90M |
| December 31, 2011 | 28.43M |
| September 30, 2011 | 38.27M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.479M
Minimum
Sep 2023
272.70M
Maximum
Jun 2022
109.75M
Average
20.48M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
| ThermoGenesis Holdings Inc | 3.278M |
| Perspective Therapeutics Inc | 0.785M |
| Electromed Inc | -0.128M |
| Xtant Medical Holdings Inc | 19.69M |
| Asensus Surgical Inc | 9.626M |